Shree Ganesh Remedies Ltd (SGRL) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Shree Ganesh Remedies Ltd. faced considerable challenges in FY25, requiring strategic recalibration.
- Q4 FY25 revenue declined 35% YoY to 24.43 crore due to a European slowdown and reduced domestic product realizations.
- Despite revenue decline, healthy volumetric growth was achieved, demonstrating underlying product demand.
- EBITDA for Q4 FY25 was 9.88 crore, down 42% YoY, with margins contracting to 40.4% due to pricing pressure and evolving product mix.
- CRAMS projects, with higher margins, contributed positively to operational profitability.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.